Hillary M. Peltier
AbbVie (United States) · 27 works · 695 citations · h-index 9
Top works
- The Total Synthesis of Tubulysin D
- ChemInform Abstract: One‐Pot Microwave‐Promoted Synthesis of Nitriles from Aldehydes via tert‐Butanesulfinyl Imines.
- One-Pot Asymmetric Synthesis of Either Diastereomer of tert-Butanesulfinyl-protected Amines from Ketones
- N -Sulfinyl Metalloenamine Conjugate Additions: Asymmetric Synthesis of Piperidines
- Design, Synthesis, and Biological Properties of Highly Potent Tubulysin D Analogues
- Catalytic Enantioselective Sulfinyl Transfer Using Cinchona Alkaloid Catalysts
- Emerging technologies for metabolite generation and structural diversification
- Expedient Synthesis of N-Methyl Tubulysin Analogues with High Cytotoxicity
- Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues
- Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
- Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2
- One-Pot Microwave-Promoted Synthesis of Nitriles from Aldehydes via tert -Butanesulfinyl Imines
- Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain
- Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma
- Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
- One‐Pot Asymmetric Synthesis of Either Diastereomer of tert‐Butanesulfinyl‐Protected Amines from Ketones.
- Catalytic Enantioselective Sulfinyl Transfer Using Cinchona Alkaloid Catalysts.
- PA-008 A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma
- OA-24 Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1–3 Prior Lines of Therapy: A Phase 1b Dose-Escalation and Safety Expansion Study
- CCDC 288331: Experimental Crystal Structure Determination